Date published: 2026-4-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

WDR21C Inhibitors

WDR21C inhibitors are a class of chemical compounds that specifically target and inhibit the activity of the WDR21C protein, a member of the WD repeat-containing protein family. WDR21C is characterized by its WD40 repeat domains, which are highly conserved structural motifs that facilitate protein-protein interactions and the formation of multiprotein complexes. These complexes are involved in regulating a wide range of cellular processes, such as signal transduction, gene expression, and protein degradation. WDR21C is believed to play a critical role in organizing and stabilizing these complexes, particularly in processes related to chromatin remodeling and DNA repair, where precise control of protein interactions is essential for maintaining cellular integrity. By inhibiting WDR21C, these compounds can disrupt the assembly and function of such protein complexes, potentially altering key molecular pathways involved in maintaining cellular homeostasis.

The mechanism of action of WDR21C inhibitors typically involves binding to the WD40 repeat domains or other critical functional regions of the WDR21C protein, preventing it from engaging with its interacting partners. This inhibition interferes with WDR21C's ability to mediate complex cellular functions, such as chromatin organization and protein turnover, by disrupting the multiprotein assemblies it regulates. Researchers utilize WDR21C inhibitors to investigate the specific biological roles of this protein, exploring how its inhibition impacts molecular pathways associated with cellular organization, genome maintenance, and protein homeostasis. By studying these inhibitors, scientists gain a deeper understanding of how WDR21C and similar WD repeat-containing proteins contribute to the regulation of cellular architecture and dynamic protein interactions, offering insights into the fundamental mechanisms governing cellular structure and function across different biological contexts.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

MLN 4924

905579-51-3sc-484814
1 mg
$286.00
1
(0)

MLN4924 is a potent inhibitor of NEDD8-activating enzyme (NAE), indirectly inhibiting the function of DCAF4L2 by preventing the neddylation of CUL4, which is crucial for DCAF4L2-mediated ubiquitination.

Curcumin

458-37-7sc-200509
sc-200509A
sc-200509B
sc-200509C
sc-200509D
sc-200509F
sc-200509E
1 g
5 g
25 g
100 g
250 g
1 kg
2.5 kg
$37.00
$69.00
$109.00
$218.00
$239.00
$879.00
$1968.00
47
(1)

Curcumin interferes with multiple signaling pathways and can indirectly influence DCAF4L2 function by modulating proteasomal degradation and ubiquitination processes.

MG-132 [Z-Leu- Leu-Leu-CHO]

133407-82-6sc-201270
sc-201270A
sc-201270B
5 mg
25 mg
100 mg
$60.00
$265.00
$1000.00
163
(3)

MG132 is a proteasome inhibitor that can indirectly affect DCAF4L2 activity by inhibiting the degradation of proteins targeted by the CUL4-DDB1-DCAF4L2 complex.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$135.00
$1085.00
115
(2)

Bortezomib, another proteasome inhibitor, functions similarly to MG132 and can modulate the activity of proteins involved in the DCAF4L2 pathway.

Thalidomide

50-35-1sc-201445
sc-201445A
100 mg
500 mg
$111.00
$357.00
8
(0)

Thalidomide and its analogs can affect the ubiquitin-proteasome system, indirectly influencing DCAF4L2-mediated protein ubiquitination.

Lenalidomide

191732-72-6sc-218656
sc-218656A
sc-218656B
10 mg
100 mg
1 g
$50.00
$374.00
$2071.00
18
(1)

Lenalidomide, a derivative of thalidomide, also affects the ubiquitin-proteasome system, potentially altering DCAF4L2 activity.

Pomalidomide

19171-19-8sc-364593
sc-364593A
sc-364593B
sc-364593C
sc-364593D
sc-364593E
5 mg
10 mg
50 mg
100 mg
500 mg
1 g
$100.00
$143.00
$312.00
$468.00
$1248.00
$1997.00
1
(1)

Pomalidomide, related to thalidomide and lenalidomide, has a similar mechanism of action and may influence DCAF4L2 activity.

VER 155008

1134156-31-2sc-358808
sc-358808A
10 mg
50 mg
$203.00
$842.00
9
(1)

VX-11e is an ERK inhibitor that can indirectly affect DCAF4L2 by modulating signaling pathways that intersect with DCAF4L2-related processes.

Selumetinib

606143-52-6sc-364613
sc-364613A
sc-364613B
sc-364613C
sc-364613D
5 mg
10 mg
100 mg
500 mg
1 g
$29.00
$82.00
$420.00
$1897.00
$3021.00
5
(1)

AZD6244, also an inhibitor of the ERK pathway, may have an indirect influence on DCAF4L2's role in protein ubiquitination.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$57.00
$100.00
$250.00
129
(3)

Sorafenib is a kinase inhibitor with broad targets, potentially affecting pathways that indirectly influence DCAF4L2 activity.